On Friday, November 22, 2013 , the FDA approved Olysio™ (simeprevir) as a new therapy to treat Hepatitis C viral infection. Diplomat will be able to distribute Olysio to patients.
Hepatitis C is a viral disease causing inflammation of the liver and can lead to decreased liver function or liver failure. Many people have no symptoms until liver damage is noted, which can take several years According to the Centers for Disease Control and Prevention (CDC), about 3.2 million Americans are infected with the Hepatitis C virus.
Simeprevir is the third protease inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Simeprevir works by blocking a specific protein needed by the Hepatitis C virus to replicate. It is used in conjunction with peginterferon-alfa and ribavirin and is the first protease inhibitor that can be taken by mouth once a day. Simeprevir is intended for adults with compensated liver disease (a diseased liver that is still functioning), including cirrhosis, who have not received treatment for their infection (treatment-naïve) or for those whose previous treatment was ineffective (treatment-experienced).
Patients infected with genotype 1a hepatitis C virus with an NS3 Q80K polymorphism exhibited a reduced effectiveness. Simeprevir’s drug label includes a recommendation to screen for this polymorphism prior to initiation of therapy and to consider alternative therapy if this strain is detected.
To learn more about Diplomat’s patient services for hepatitis C, visit our website. You may also call us directly at 877.977.9118 or, if your inquiry is not urgent, email us at firstname.lastname@example.org.
Diplomat joins advocates, patients, caregivers, and physicians every December to lend our voice to HIV and AIDS awareness month. This is an opportunity to educate friends and family members about HIV and AIDS, encourage safe behaviors and regular testing, and work together.
What is HIV?
HIV stands for “human immunodeficiency virus.” HIV, which is only able to infect humans, attacks the cells of the human immune system (T-cells or CD4 cells). After getting inside the cells of the immune system, HIV uses the machinery inside those cells to make copies of itself, and then destroys those cells. This results in a weakened immune system.
What is AIDS?
When the human immune system is weak, it is less capable of fighting off infection. If an HIV infection is left untreated, the patient may develop acquired immunodeficiency syndrome (AIDS). A patient is considered to have AIDS once the amount of CD4 cells in the body falls below 200 cells/mm3.
Patients with HIV can also be diagnosed with AIDS once they develop an “opportunistic infection”. Opportunistic infections are caused by bacteria, viruses, or parasites that do not usually cause infections in otherwise healthy patients. These bacteria, viruses, and parasites take advantage of the patients’ weakened immune system and can cause very serious, even life-threatening, illnesses.
Read more ›
Every year, on December 1, patients, caregivers, physicians, and advocates who have been affected by HIV/AIDS come together to commemorate World AIDS Day.
This year’s theme is “Shared Responsibility: Strengthening Results for an AIDS-Free Generation.” A united front can help educate others about HIV and how its spread as well as help to reduce transmission of the virus. There are many ways to get involved not only today but throughout the year.
One key way to share the responsibility of moving towards an AIDS-free generation is committing to regular HIV testing. You can find the nearest HIV testing site by visiting the HIV Testing Sites & Care Services Locator online. The CDC also has a National HIV and STD Testing Resources database that can come in handy. HIV testing is recommended annually; learn more about why to get an HIV test here.
Read more ›